Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 6;38:342. doi: 10.1186/s13046-019-1342-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 6 — CWP232291 inhibits the growth of prostate cancer xenografts. a Mice bearing 22Rv1 tumors were treated with CWP232291 (28 days, 50 mg/kg/day or 100 mg/kg/day). Changes in tumor volume of the 22Rv1 xenografted mice are shown. Results are expressed as the means ± SD of six mice. b Body weight of the 22Rv1 xenografted mice is shown. Results are expressed as means ± SD. c Tumor weight of the 22Rv1 xenografted mice is shown. Results are expressed as means ± SEM. *P < 0.05 by one-way ANOVA. d Representative tumors of the 22Rv1 xenografted mice. e Western blot analysis of β-catenin, cleaved caspase-3, and GAPDH in 22Rv1 in two pairs of xenografted tumors. One western blot was randomly selected from the control group and one from the treatment group. Western blots were performed in triplicates and repeated independently three times